Biomarkers in Alzheimer Disease and Other Dementias: What's Next into Pathophysiology to Support Clinical Practice and Drug Development

Anastasia Bougea

doi:10.3390/medicina58101374

Biomarkers in Alzheimer Disease and Other Dementias: What's Next into Pathophysiology to Support Clinical Practice and Drug Development

Medicina (Kaunas). 2022 Sep 30;58(10):1374. doi: 10.3390/medicina58101374.

Author

Anastasia Bougea¹

Affiliation

¹ 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, 72-74 Vassilisis Sofia's Avenue, 11528 Athens, Greece.

Abstract

Neurodegenerative diseases are a heterogeneous group of disorders characterized by gradual progressive neuronal loss in the central nervous system [...].

Publication types

Editorial

MeSH terms

Alzheimer Disease* / drug therapy
Biomarkers
Drug Development
Humans

Substances

Biomarkers

Grants and funding

This research received no external funding.